• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Study.古塞库单抗诱导治疗对中度至重度活动性溃疡性结肠炎的早期症状改善：3期QUASAR研究结果
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):2-3.
2
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.古塞单抗治疗中重度活动性溃疡性结肠炎患者：QUASAR 期 2b 诱导研究。
Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1.
3
The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study.古塞库单抗诱导治疗中重度活动性溃疡性结肠炎患者的疗效和安全性：3期QUASAR诱导研究结果
Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):9-10.
4
The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12.古塞库单抗诱导治疗中重度活动性溃疡性结肠炎患者的疗效和安全性：2b期QUASAR研究第12周结果
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):12.
5
The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced Therapy.古塞库单抗诱导疗法对中度至重度活动性溃疡性结肠炎患者的疗效：QUASAR 2b期诱导治疗第12周时既往对先进疗法反应不足或不耐受患者的结果
Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):12-13.
6
The Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Maintenance Study.古塞库单抗作为中度至重度活动性溃疡性结肠炎患者维持治疗的疗效和安全性：3期QUASAR维持研究结果
Gastroenterol Hepatol (N Y). 2024 Jul;20(7 Suppl 6):8-9.
7
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.古塞库单抗联合戈利木单抗与古塞库单抗或戈利木单抗单药治疗溃疡性结肠炎患者的疗效比较（VEGA）：一项随机、双盲、对照、2期概念验证试验
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1.
8
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.以艾托珠单抗对比阿达木单抗或安慰剂作为中度至重度活动性溃疡性结肠炎诱导治疗（HIBISCUS）：两项3期随机对照试验
Lancet Gastroenterol Hepatol. 2022 Jan;7(1):17-27. doi: 10.1016/S2468-1253(21)00338-1. Epub 2021 Nov 17.
9
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.乌帕替尼作为中度至重度活动溃疡性结肠炎的诱导和维持治疗：三项 3 期、多中心、双盲、随机临床试验的结果。
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
10
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.依特利珠单抗与英夫利昔单抗治疗中重度活动性溃疡性结肠炎（GARDENIA）的随机、双盲、双模拟、3 期研究。
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17.

引用本文的文献

1
Recent advances and research progress regarding monoclonal antibodies for chronic graft-versus-host disease.慢性移植物抗宿主病单克隆抗体的最新进展与研究成果
Heliyon. 2024 Sep 25;10(19):e38460. doi: 10.1016/j.heliyon.2024.e38460. eCollection 2024 Oct 15.
2
Highlights in Ulcerative Colitis From the American College of Gastroenterology 2023 Annual Scientific Meeting: Commentary.美国胃肠病学会2023年年度科学会议溃疡性结肠炎亮点：评论
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):13-18.

本文引用的文献

1
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.古塞单抗治疗中重度活动性溃疡性结肠炎患者：QUASAR 期 2b 诱导研究。
Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1.
2
Blockade of IL-23: What is in the Pipeline?阻断白细胞介素-23：有哪些在研药物？
J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72. doi: 10.1093/ecco-jcc/jjab185.

Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Study.

出版信息

Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):2-3.

PMID:38445181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10910377/
Abstract
摘要